Tyrosine kinases as targets for cancer therapy.
Explore this paper's citation graph
Summary
A comprehensive review discusses the molecular and clinical aspects of tyrosine kinases, enzymes that catalyze the transfer of phosphate from ATP to tyrosin residues in polypeptides.
- Type
- review
- Published
- 2005-07-14
- Cited by
- 1,468
- References
- 124
- Access
- Open access
- OpenAlex
- https://openalex.org/W2164452916
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32629397
Keywords
Tyrosine kinase, Receptor tyrosine kinase, Tyrosine, Medicine, Kinase
References
- Dysfunction of the RET receptor in human cancer.
- Monoclonal antibody therapy for breast cancer: herceptin.
- TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.
- Improving the evaluation of new cancer treatments: challenges and opportunities
- Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
- The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts.
- Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
- Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.
- Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.
- Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
- Phase II study of imatinib in patients with small cell lung cancer.
- Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.
- After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
- Erlotinib in lung cancer - molecular and clinical predictors of outcome.
- The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1
- A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
- A gain-of-function mutation of JAK2 in myeloproliferative disorders.
- Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
- Single cell profiling of potentiated phospho-protein networks in cancer cells.
- KIT mutations are common in testicular seminomas.
Cited by
- Advances in Cancer Stem Cell Biology
- Receptor tyrosine kinases in osteosarcoma: not just the usual suspects.
- Primary resistance to ATP-competitive mTOR inhibitors for the treatment of solid tumors
- Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
- The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV‐negative cases of classical Hodgkin's lymphoma
- Oncogenes in Myeloproliferative Disorders
- Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
- Keloid scarring: new treatments ahead.
- Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours
- Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases
- Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
- Evaluation of anastomotic strength and drug safety after short-term sunitinib administration in rabbits.
- Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
- ROR1 contributes to melanoma cell growth and migration by regulating N‐cadherin expression via the PI3K/Akt pathway
- Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
- The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study
- Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
- Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
- Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator
- Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray
Related papers
- Involvement of the membrane distal catalytic domain in pervanadate-induced tyrosine phosphorylation of receptor protein-tyrosine phosphatase alpha.
- Negative regulation of a protein tyrosine phosphatase by tyrosine phosphorylation.
- Tyrosine phosphorylation as a marker for aberrantly regulated growth‐promoting pathways in cell lines derived from head and neck malignancies
- Increased tyrosine phosphorylation in ras transformed fibroblasts occurs prior to manifestation of the transformed phenotype.
- Investigation of factors that influence phosphorylation of pp60c-src on tyrosine 527
- Genomic Survey of Premetazoans Shows Deep Conservation of Cytoplasmic Tyrosine Kinases and Multiple Radiations of Receptor Tyrosine Kinases
- Tyrosine-phosphorylated proteins: mediators of signal transduction from the tyrosine kinases.
- MD-2 interacts with Lyn kinase and is tyrosine phosphorylated following LPS-induced activation of the Toll-like receptor 4 signaling pathway